[go: up one dir, main page]

UA95458C2 - Вакцина против pcv-2 у mda-положительных поросят - Google Patents

Вакцина против pcv-2 у mda-положительных поросят

Info

Publication number
UA95458C2
UA95458C2 UAA200803112A UAA200803112A UA95458C2 UA 95458 C2 UA95458 C2 UA 95458C2 UA A200803112 A UAA200803112 A UA A200803112A UA A200803112 A UAA200803112 A UA A200803112A UA 95458 C2 UA95458 C2 UA 95458C2
Authority
UA
Ukraine
Prior art keywords
pcv
vaccine
orf
protein
mda positive
Prior art date
Application number
UAA200803112A
Other languages
English (en)
Ukrainian (uk)
Inventor
Франк Руринк
Вунсел Питер Ван
Original Assignee
Интервет Интернешонал Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482131&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95458(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Интервет Интернешонал Б.В. filed Critical Интервет Интернешонал Б.В.
Publication of UA95458C2 publication Critical patent/UA95458C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/10011Circoviridae
    • C12N2750/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UAA200803112A 2005-09-09 2006-09-08 Вакцина против pcv-2 у mda-положительных поросят UA95458C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108299 2005-09-09

Publications (1)

Publication Number Publication Date
UA95458C2 true UA95458C2 (ru) 2011-08-10

Family

ID=35482131

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803112A UA95458C2 (ru) 2005-09-09 2006-09-08 Вакцина против pcv-2 у mda-положительных поросят

Country Status (14)

Country Link
US (2) US20080248061A1 (ru)
EP (1) EP1926496B1 (ru)
JP (1) JP5106398B2 (ru)
KR (1) KR101347503B1 (ru)
CN (1) CN101277717A (ru)
AU (1) AU2006289102C1 (ru)
BR (1) BRPI0615862A2 (ru)
CA (1) CA2620727C (ru)
DK (1) DK1926496T3 (ru)
ES (1) ES2425228T3 (ru)
PL (1) PL1926496T3 (ru)
RU (1) RU2389506C2 (ru)
UA (1) UA95458C2 (ru)
WO (1) WO2007028823A1 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
ES2532861T3 (es) * 2004-12-30 2015-04-01 Boehringer Ingelheim Vetmedica, Inc. Composiciones inmunogénicas para PCV2 para uso en un método de prevenir una infección por PCV2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
PT3127551T (pt) * 2005-12-29 2020-10-09 Boehringer Ingelheim Animal Health Usa Inc Composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CN101558169B (zh) 2006-12-15 2017-08-04 贝林格尔.英格海姆维特梅迪卡有限公司 以pcv2抗原治疗猪
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌(Lawsonia intracellularis)、豬肺炎黴漿菌(Mycoplasma hyopneumoniae)及豬環狀病毒(Porcine circo virus)用疫苗
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌(Lawsonia intracellularis)用疫苗
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
CN101875941A (zh) * 2010-03-09 2010-11-03 胡文锋 一种人工改造合成的dORF2art基因及其编码的蛋白质
AU2010357208A1 (en) 2010-07-08 2013-02-21 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
CN101920012B (zh) * 2010-07-22 2012-12-12 普莱柯生物工程股份有限公司 利用家蚕生物反应器生产猪圆环病毒2型重组衣壳蛋白亚单位疫苗的方法及其产品
WO2012076623A1 (en) 2010-12-08 2012-06-14 Intervet International B.V. A method to quantify the amount of a biological substance in a sample and a kit for performing the method
EP2564869A1 (en) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof
CN102352347A (zh) * 2011-10-14 2012-02-15 浙江诺倍威生物技术有限公司 Pcv2重组杆状病毒构建及其亚单位疫苗制备方法
CN102517331A (zh) * 2011-12-26 2012-06-27 武汉中博生物股份有限公司 一种猪圆环病毒2型亚单位疫苗及其制备方法和其应用
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
CN102978232B (zh) * 2012-08-23 2014-07-16 郑州后羿制药有限公司 一种IPTG诱导猪圆环病毒2型重组Cap蛋白表达的方法
BR102013001893B1 (pt) 2013-01-25 2022-01-25 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
KR101527832B1 (ko) * 2013-05-28 2015-06-11 대한민국 돼지써코바이러스 2형(pcv2)의 orf2 재조합 유전자, 전달 벡터, 재조합 배큘로바이러스, 돼지써코바이러스 2형(pcv2) 재조합 캡시드 단백질 및 그의 제조방법
EP4091629A1 (en) * 2013-09-25 2022-11-23 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
KR102409183B1 (ko) 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Pcv2 orf2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
CN104548083B (zh) * 2013-10-22 2019-05-07 洛阳赛威生物科技有限公司 一种疫苗组合物及其制备方法和应用
BR112016012435A8 (pt) 2013-12-03 2018-01-30 Intervet Int Bv vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
US10130699B2 (en) 2013-12-03 2018-11-20 Intervet Inc. Vaccine against Lawsonia intracellularis and porcine circovirus 2
CN106999567B (zh) 2014-12-11 2021-08-31 英特维特国际股份有限公司 用于即用型PCV2/M.hyo组合疫苗的方法
WO2017162720A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
RU2018137034A (ru) 2016-03-23 2020-04-23 Интервет Интернэшнл Б.В. Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
JP2019509302A (ja) 2016-03-23 2019-04-04 インターベット インターナショナル ベー. フェー. アルブミンを含むpcv2及びprrsウイルス感染症に対する混合ワクチン
CN105785037B (zh) * 2016-03-30 2017-09-19 中国农业科学院兰州兽医研究所 猪圆环病毒2型抗体快速检测层析试纸条及制备方法
US11311614B2 (en) 2017-04-13 2022-04-26 Intervet Inc. Vaccines containing swine pathogens for associated non-mixed use
WO2019022463A2 (ko) * 2017-07-24 2019-01-31 (주)제이비바이오텍 면역원성시스템 및 이를 포함한 동물 백신
EP3661548B1 (en) 2017-08-03 2024-06-26 Intervet International B.V. A vaccine comprising a pcv2 orf2 protein of genotype 2b
CA3078281C (en) 2017-10-17 2023-02-21 Intervet International B.V. Recombinant expression of pcv2b orf2 protein in insect cells
TW202003027A (zh) 2018-03-26 2020-01-16 美商百靈佳殷格翰動物保健美國有限公司 製造免疫原組合物之方法
KR20220062345A (ko) 2019-09-12 2022-05-16 인터벳 인터내셔널 비.브이. 피내 투여용 복합 백신
EP4138896A1 (en) 2020-04-20 2023-03-01 Intervet International B.V. A combination of vaccines to prophylactically treat a pig
CN116457004A (zh) 2020-10-29 2023-07-18 英特维特国际股份有限公司 用于保护猪免于各种疾病的组合疫苗
TW202508619A (zh) 2023-05-03 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 用於誘導免疫反應之方法
KR20260005383A (ko) 2023-05-03 2026-01-09 베링거잉겔하임베트메디카게엠베하 돼지에 의한 자가 투여에 유용한 면역원성 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382271B1 (en) * 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
EP0835930B1 (en) * 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations

Also Published As

Publication number Publication date
AU2006289102C1 (en) 2017-11-30
CN101277717A (zh) 2008-10-01
AU2006289102A1 (en) 2007-03-15
KR20080042159A (ko) 2008-05-14
EP1926496B1 (en) 2013-06-26
KR101347503B1 (ko) 2014-01-02
JP5106398B2 (ja) 2012-12-26
CA2620727C (en) 2015-06-16
AU2006289102B2 (en) 2011-12-15
PL1926496T3 (pl) 2014-02-28
DK1926496T3 (da) 2013-09-30
BRPI0615862A2 (pt) 2011-05-31
RU2389506C2 (ru) 2010-05-20
US20080248061A1 (en) 2008-10-09
EP1926496A1 (en) 2008-06-04
CA2620727A1 (en) 2007-03-15
ES2425228T3 (es) 2013-10-14
US20110064765A1 (en) 2011-03-17
JP2009507811A (ja) 2009-02-26
WO2007028823A1 (en) 2007-03-15
US8008001B2 (en) 2011-08-30
RU2008113763A (ru) 2009-10-20

Similar Documents

Publication Publication Date Title
UA95458C2 (ru) Вакцина против pcv-2 у mda-положительных поросят
UA99708C2 (ru) Одноразовая доза поливалентной комбинированной вакцины, которая включает антиген цирковируса свиней типа 2
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
MX2009006541A (es) Tratamiento de prdc en cerdos.
MY152149A (en) Prevention and treatment of sub-clinical pcvd
AU2168902A (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
MXPA06005639A (es) Adyuvante antimicrobiano.
ATE496021T1 (de) Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
IL187293A0 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
NO20082376L (no) Farmasoytiske sammensetninger
PL2054431T3 (pl) Konformery adhezyn bakteryjnych
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
TN2012000431A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
ATE479440T1 (de) Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen
PL1965809T3 (pl) Kompozycje do poprawiania zdrowia jelit i użytkowości zwierząt zawierające beta-glukany i alfa-fukany
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2007047728A3 (en) Compositions and methods for the treatment of canine influenza virus disease
TW200609200A (en) Preparation of levalbuterol hydrochloride
WO2007077318A3 (fr) Utilisation d'un extrait peptidique de riz en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
SG163571A1 (en) Rotavirus vaccine inducing heterotypic cross protection